Kim SY - Search Results

1

Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy.

Hong YS, Lee J, Kim KP, Lee JL, Park YS, Park JO, Park SH, Kim SY, Baek JY, Kim JH, Lee KW, Kim TY, Kim TW. Hong YS, et al. Among authors: kim tw, kim kp, kim ty, kim sy, kim jh. Invest New Drugs. 2013 Feb;31(1):183-91. doi: 10.1007/s10637-012-9853-3. Epub 2012 Jul 11. Invest New Drugs. 2013. PMID: 22782485 Clinical Trial.

2

Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin.

Kim SY, Kim HP, Kim YJ, Oh DY, Im SA, Lee D, Jong HS, Kim TY, Bang YJ. Kim SY, et al. Among authors: kim yj, kim ty, kim hp. Int J Oncol. 2008 Jan;32(1):89-95. Int J Oncol. 2008. PMID: 18097546

3

Pathologic complete response after palliative 3rd line chemotherapy with capecitabine alone in metastatic colorectal cancer.

Cho HJ, Kim SJ, Kim SY, Han HS, Hong YS, Kim SH, Lim SB, Jung KH, Chang HJ, Hong EK. Cho HJ, et al. Among authors: kim sh, kim sy, kim sj. Cancer Chemother Pharmacol. 2009 Feb;63(3):549-53. doi: 10.1007/s00280-008-0766-y. Epub 2008 May 7. Cancer Chemother Pharmacol. 2009. PMID: 18461328

4

A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer.

Kim SY, Hong YS, Kim BC, Park JW, Choi HS, Jeong SY, Kim DY, Hong CW, Sohn DK, Jung KH. Kim SY, et al. Among authors: kim bc, kim dy. Invest New Drugs. 2009 Jun;27(3):269-74. doi: 10.1007/s10637-008-9177-5. Epub 2008 Sep 25. Invest New Drugs. 2009. PMID: 18815728 Clinical Trial.

5

Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.

Han HS, Chang HJ, Hong YS, Kim SY, Lee KS, Jung KH. Han HS, et al. Among authors: kim sy. Dis Colon Rectum. 2009 Jun;52(6):1144-51; discussion 1152-3. doi: 10.1007/DCR.0b013e31819edbf9. Dis Colon Rectum. 2009. PMID: 19581859

6

Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer.

Hong YS, Cho HJ, Kim SY, Jung KH, Park JW, Choi HS, Oh JH, Kim BC, Sohn DK, Kim DY, Chang HJ. Hong YS, et al. Among authors: kim bc, kim dy, kim sy. BMC Cancer. 2009 Jul 21;9:246. doi: 10.1186/1471-2407-9-246. BMC Cancer. 2009. PMID: 19619339 Free PMC article.

7

Resected colorectal liver metastases: does the survival differ according to postoperative chemotherapy regimen?

Kim SY, Kim HJ, Hong YS, Jung KH, Park JW, Choi HS, Oh JH, Park SJ, Kim SH, Nam BH, Chang HJ, Kim DY. Kim SY, et al. Among authors: kim hj, kim sh, kim dy. J Surg Oncol. 2009 Dec 15;100(8):713-8. doi: 10.1002/jso.21403. J Surg Oncol. 2009. PMID: 19771561

8

Pathologic nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.

Kim TH, Chang HJ, Kim DY, Jung KH, Hong YS, Kim SY, Park JW, Oh JH, Lim SB, Choi HS, Jeong SY. Kim TH, et al. Among authors: kim dy, kim sy. Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1158-65. doi: 10.1016/j.ijrobp.2009.06.019. Epub 2009 Sep 30. Int J Radiat Oncol Biol Phys. 2010. PMID: 19800178

9

Prognostic impact of peritonealisation in rectal cancer treated with preoperative chemoradiotherapy: extraperitoneal versus intraperitoneal rectal cancer.

Hwang MR, Park JW, Kim DY, Chang HJ, Hong YS, Kim SY, Choi HS, Jeong SY, Oh JH. Hwang MR, et al. Among authors: kim dy, kim sy. Radiother Oncol. 2010 Mar;94(3):353-8. doi: 10.1016/j.radonc.2009.11.005. Epub 2009 Dec 16. Radiother Oncol. 2010. PMID: 20006392 Clinical Trial.

10

Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial.

Kang SB, Park JW, Jeong SY, Nam BH, Choi HS, Kim DW, Lim SB, Lee TG, Kim DY, Kim JS, Chang HJ, Lee HS, Kim SY, Jung KH, Hong YS, Kim JH, Sohn DK, Kim DH, Oh JH. Kang SB, et al. Among authors: kim dw, kim dh, kim dy, kim sy, kim js, kim jh. Lancet Oncol. 2010 Jul;11(7):637-45. doi: 10.1016/S1470-2045(10)70131-5. Epub 2010 Jun 16. Lancet Oncol. 2010. PMID: 20610322 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12,077 results

Search Page